Celgene to pay GlobeImmune up to $540 million in tarmogen deal
This article was originally published in Scrip
Executive Summary
Celgene is to pay the US private company GlobeImmune $40 million up front for the exclusive rights to all of its oncology programmes, including the Tarmogen technology-based product GI-4000.